Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 4, 2008

Bio Products Laboratory to Produce GammaCan’s Cancer Immunotherapy

  • Bio Products Laboratory’s (BPL) will manufacture GammaCan’s cancer immunotherapy, VitiGam™. The candidate is being developed for Stage III and Stage IV melanoma. Currently, GammaCan is in pre-IND meetings with the FDA related to the IgG-based product.

    BPL will manufacture the compound from plasma derived from donors suffering from vitiligo utilizing its Gammaplex process. The multiyear agreement covers clinical-trial and commercial-level supply of VitiGam.

    In addition, the agreement provides that BPL will provide the company with technical, scientific, and other data including specific support for its U.S. regulatory filings and future regulatory approvals in other markets.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »